Supply chain durability for new offerings such as liraglutide was flagged as a critical factor for sustained growth. Hims & Hers closed 2024 with strong financial performance and significant ...

Hims & Hers Health, Inc. (HIMS) reported $481.14 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 95.1%. EPS of $0.11 for the same period compares to ...

Check out this evening’s top movers from around Wall Street, compiled by The Fly.Discover the Best Stocks and Maximize Your Portfolio: See what ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...